Literature DB >> 15068854

DNA immunisation with minimalistic expression constructs.

S Moreno1, L López-Fuertes, A J Vila-Coro, F Sack, C A Smith, S A Konig, B Wittig, M Schroff, C Juhls, C Junghans, M Timón.   

Abstract

The low efficacy obtained in large animals makes plasmid-based DNA vaccines commercially unviable. Another concern is the presence of antibiotic resistance markers on virtually all conventional plasmids. Here we describe the use of minimalistic, immunogenically defined gene expression (MIDGE) vectors for DNA vaccination. MIDGE are linear, covalently-closed vectors containing all the essential information for gene expression and none of the non-essential and potentially dangerous plasmid backbone sequences. MIDGE vectors can also be chemically modified on both ends at defined positions allowing targeting of the DNA to specific cell types or cellular compartments. Immunisation of mice with simple and end-modified MIDGE vectors showed that they are efficacious tools to generate and/or manipulate antigen-specific immune responses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15068854     DOI: 10.1016/j.vaccine.2003.09.051

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Extended and stable gene expression via nucleofection of MIDGE construct into adult human marrow mesenchymal stromal cells.

Authors:  P L Mok; S K Cheong; C F Leong; K H Chua; O Ainoon
Journal:  Cytotechnology       Date:  2011-12-10       Impact factor: 2.058

2.  Advanced Design of Dumbbell-shaped Genetic Minimal Vectors Improves Non-coding and Coding RNA Expression.

Authors:  Xiaoou Jiang; Han Yu; Cui Rong Teo; Genim Siu Xian Tan; Sok Chin Goh; Parasvi Patel; Yiqiang Kevin Chua; Nasirah Banu Sahul Hameed; Antonio Bertoletti; Volker Patzel
Journal:  Mol Ther       Date:  2016-06-30       Impact factor: 11.454

3.  Novel linear DNA vaccines induce protective immune responses against lethal infection with influenza virus type A/H5N1.

Authors:  Frédéric Kendirgi; Nadezda E Yun; Nathaniel S Linde; Michele A Zacks; Jeanon N Smith; Jennifer K Smith; Harilyn McMicken; Yin Chen; Slobodan Paessler
Journal:  Hum Vaccin       Date:  2008-11-21

4.  Immune response of healthy horses to DNA constructs formulated with a cationic lipid transfection reagent.

Authors:  Christiane L Schnabel; P Steinig; M Koy; H-J Schuberth; C Juhls; D Oswald; B Wittig; S Willenbrock; H Murua Escobar; C Pfarrer; B Wagner; P Jaehnig; A Moritz; K Feige; J-M V Cavalleri
Journal:  BMC Vet Res       Date:  2015-06-23       Impact factor: 2.741

5.  Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccine.

Authors:  O Riede; K Seifert; D Oswald; A Endmann; C Hock; A Winkler; F J Salguero; M Schroff; S L Croft; C Juhls
Journal:  Gene Ther       Date:  2015-04-30       Impact factor: 5.250

6.  Advances in Non-Viral DNA Vectors for Gene Therapy.

Authors:  Cinnamon L Hardee; Lirio Milenka Arévalo-Soliz; Benjamin D Hornstein; Lynn Zechiedrich
Journal:  Genes (Basel)       Date:  2017-02-10       Impact factor: 4.096

7.  Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines.

Authors:  A A Walters; E Kinnear; R J Shattock; J U McDonald; L J Caproni; N Porter; J S Tregoning
Journal:  Gene Ther       Date:  2014-05-15       Impact factor: 5.250

8.  Cationic lipid-formulated DNA vaccine against hepatitis B virus: immunogenicity of MIDGE-Th1 vectors encoding small and large surface antigen in comparison to a licensed protein vaccine.

Authors:  Anne Endmann; Katharina Klünder; Kerstin Kapp; Oliver Riede; Detlef Oswald; Eduard G Talman; Matthias Schroff; Christiane Kleuss; Marcel H J Ruiters; Christiane Juhls
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.